SCHEMBL4740320

SCHEMBL4740320

CCOC(=O)C1(C(C)=O)CC=C(C)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.35
BRD4 O60885 1/20 0.35
OPRM1 P35372 6/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
OPRD1 P41143 3/20 0.33
OPRK1 P41145 3/20 0.33
SLC22A1 O15245 1/20 0.33
SLC6A4 P31645 1/20 0.33
ADRA1A P35348 1/20 0.33
KCNH2 Q12809 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ATM Q13315 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32
ALOX15 P16050 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL610749 0.91 POLB (0.38) POLBBRD4OPRM1SMN1; SMN2OPRD1
SCHEMBL15624086 0.78 OPRM1 (0.38) POLBBRD4OPRM1SMN1; SMN2OPRD1
SCHEMBL23065403 0.78 OPRM1 (0.38) POLBOPRM1SMN1; SMN2OPRD1OPRK1
SCHEMBL10844913 0.77 GRM4 (0.30)
SCHEMBL4740340 0.77 ALDH1A1 (0.39) POLBOPRM1SMN1; SMN2OPRD1OPRK1
SCHEMBL4740325 0.77 POLB (0.40) POLBBRD4OPRM1SMN1; SMN2OPRD1
SCHEMBL10938727 0.75 SMN1; SMN2 (0.39) POLBOPRM1SMN1; SMN2OPRD1OPRK1
SCHEMBL16107365 0.75 SMN1; SMN2 (0.39) POLBBRD4OPRM1SMN1; SMN2OPRD1
SCHEMBL10118790 0.75 POLB (0.36) POLBBRD4OPRM1SMN1; SMN2OPRD1
SCHEMBL24425852 0.74 ATM (0.35) POLBBRD4OPRM1SMN1; SMN2OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8361922-B2 Organometallic ruthenium complexes and related methods for the preparation of tetra-substituted and other hindered olefins MATERIA, INC. (US) 2013-01-29 US disclosed
US-20120123133-A1 ORGANOMETALLIC RUTHENIUM COMPLEXES AND RELATED METHODS FOR THE PREPARATION OF TETRA-SUBSTITUTED AND OTHER HINDERED OLEFINS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2012-05-17 US disclosed
EP-0081893-B1 OXABICYCLOALKANE HERBICIDES SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1987-03-04 EP disclosed
EP-0081893-A2 Oxabicycloalkane herbicides SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1983-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120123133-A1 ORGANOMETALLIC RUTHENIUM COMPLEXES AND RELATED METHODS FOR THE PREPARATION OF TETRA-SUBSTITUTED AND OTHER HINDERED OLEFINS ORC3, OXER1, CBR3 POLB 2244/4885BRD4 1094/4885OPRM1 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.